Bevacizumab (Avastin): Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
VisualWikitext
No edit summary
No edit summary
 
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=Bevacizumab (Avastin)
|drug_name=Procarbazine
|overview=Bevacizumab, sold under the brand name Avastin, is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By targeting VEGF, Avastin reduces the blood supply to tumors, which can slow their growth. It is FDA-approved for the treatment of recurrent glioblastoma and is often combined with other therapies to manage this aggressive cancer.
|FDA_approval=Yes
|FDA_approval=Yes, for recurrent glioblastoma
|used_for=Glioblastoma
|used_for=Management of recurrent glioblastoma and investigational use in newly diagnosed glioblastoma as part of combination therapies
|clinical_trial_phase=Not specified
|clinical_trial_phase=Phase III for glioblastoma
|common_side_effects=Hematological toxicity, nausea, and neurological effects
|common_side_effects=Hypertension, proteinuria, hemorrhage, gastrointestinal perforation, thromboembolic events, and wound healing complications
|OS_with=Not specified
|OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months
|usefulness_rating=3
|PFS_with=AVAglio trial: 10.6 months; RTOG trial: 10 months
|notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
|OS_without=AVAglio trial: 16.7 months; RTOG trial: 16.1 months
|PFS_without=AVAglio trial: 6.2 months; RTOG trial: 7.3 months
|usefulness_rating=4
|links=
|toxicity_level=3
|treatment_category=Other Chemotherapy and Cancer Drugs
|treatment_category=Other Chemotherapy and Cancer Drugs
|toxicity_explanation=Bevacizumab has a moderate toxicity profile. While it can extend progression-free survival and improve quality of life in glioblastoma patients, it can cause significant side effects. These include hypertension, proteinuria, bleeding, and rare but severe complications like gastrointestinal perforation and thromboembolic events. Regular monitoring and management of side effects are essential during treatment.
|toxicity_level=4
|notes=Bevacizumab has shown efficacy in improving progression-free survival in glioblastoma patients but does not significantly extend overall survival when compared to its use at recurrence. Its use is associated with better quality of life and delayed progression of symptoms. However, careful monitoring for adverse effects is necessary.
|toxicity_explanation=The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.
 
|book_text=Temodar has also been combined with procarbazine (64). While the report of that study
=== Avastin in Clinical Trials ===
did not include the PFS-6 statistic, it did report an unusually high percentage of tumor
Two large randomized Phase III trials, AVAglio and RTOG, evaluated the addition of Bevacizumab to the Stupp protocol for newly diagnosed glioblastoma. In the AVAglio trial, median progression-free survival (PFS) was significantly longer for patients receiving Avastin (10.6 months) compared to the control group (6.2 months). However, overall survival (OS) was not significantly different (16.8 months vs. 16.7 months). Similarly, the RTOG trial reported a median PFS of 10 months for the Avastin group versus 7.3 months for the control group, with OS of 15.7 months for the Avastin group and 16.1 months for the control.
regressions, suggesting that this combination might be effective.
 
|overview=Procarbazine is an FDA-approved chemotherapy drug primarily used for treating glioblastoma, known for its effectiveness when combined with Temodar, as evidenced by a high percentage of tumor regressions. However, it carries a toxicity level of 4, with common side effects including hematological toxicity, nausea, and neurological effects that can significantly impact daily life.}}
=== Quality of Life and Progression-Free Survival ===
Both trials highlighted that while Avastin does not improve overall survival when administered as part of initial treatment, it can delay tumor progression and potentially improve the quality of life for patients. Notably, many control group patients received Avastin after tumor progression, making these studies a comparison of early versus delayed use of the drug.
 
=== Future Research and Combinations ===
Ongoing studies are exploring combinations of Bevacizumab with other agents, including targeted therapies, immunotherapies, and radiosensitizers, to enhance its efficacy. These efforts aim to optimize the therapeutic window and potentially improve overall survival for glioblastoma patients.<ref>{{Cite web |title=Clinical Trials of Bevacizumab in Glioblastoma |url=https://www.ncbi.nlm.nih.gov |publisher=PubMed |accessdate=2024-08-12}}</ref>
}}

Latest revision as of 01:22, 18 January 2025

Property Information
Drug Name Procarbazine
Overview Procarbazine is an FDA-approved chemotherapy drug primarily used for treating glioblastoma, known for its effectiveness when combined with Temodar, as evidenced by a high percentage of tumor regressions. However, it carries a toxicity level of 4, with common side effects including hematological toxicity, nausea, and neurological effects that can significantly impact daily life.
FDA Approval Yes
Used for Glioblastoma
Clinical Trial Phase Not specified
Clinical Trial Explanation Not specified
Common Side Effects Hematological toxicity, nausea, and neurological effects
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 4
Toxicity Explanation The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.

Notes: Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.


From Ben Williams Book: Temodar has also been combined with procarbazine (64). While the report of that study did not include the PFS-6 statistic, it did report an unusually high percentage of tumor regressions, suggesting that this combination might be effective.Property "Has original text" (as page type) with input value "Temodar has also been combined with procarbazine (64). While the report of that study</br>did not include the PFS-6 statistic, it did report an unusually high percentage of tumor</br>regressions, suggesting that this combination might be effective." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Bevacizumab_(Avastin)&oldid=94204"